Business Context and Reporting Period
This Form 8-K is filed by Petra Acquisition, Inc. (Petra) on November 24, 2021, reporting events occurring on November 13, 2021. Petra is a special purpose acquisition company (SPAC) that entered into a definitive business combination agreement with Revelation Biosciences, Inc. (Revelation) on August 29, 2021. The filing details the extension of the deadline to consummate this proposed merger.
Key Financial Metrics and Liquidity
The filing does not provide comprehensive financial statements, revenue, profit, or margin data for either entity. It focuses on liquidity related to the SPAC trust account:
- Trust Account Contribution: On November 17, 2021, a contribution of $160,957 was deposited into Petra's Trust Account.
- Contribution Rate: This amount equates to $0.034 for each share of common stock issued in the IPO that was not redeemed.
- Previous Extension: A similar contribution of $160,957 was made on October 12, 2021, for the first extension.
- Debt and Cash Flow: The filing text does not provide specific values for total debt, operating cash flow, or current liquidity positions outside of the trust account contributions.
Material Changes
The primary material change reported is the extension of the business combination deadline:
- Deadline Extension: Petra extended the date by which it must consummate a business combination from November 13, 2021, to December 13, 2021.
- Future Options: The amendment to Petra's certificate of incorporation provides options to further extend the deadline to January 13, 2022 (noted as January 13, 2021 in the source text, likely a typo for 2022).
- Stockholder Approval: Stockholders previously approved the amendment on October 8, 2021, enabling these extensions.
Outlook, Risks, and Management Commentary
Management highlights significant risks and uncertainties regarding the transaction and Revelation's operations:
- Transaction Risks: Risks include the failure to obtain stockholder approval, inability to meet closing conditions, and uncertainty regarding the amount of cash remaining in the trust account due to potential redemptions by Petra stockholders.
- Operational Risks: Revelation faces risks related to the successful completion of the RVL-CLR01 clinical study, enrollment delays, adverse safety events, and regulatory approval for product candidates (REVTx-99, REVTx-200, REVDx-501).
- Financial Uncertainty: There is no minimum funding level required in the trust fund to close the transaction, creating uncertainty about the cash proceeds available to Revelation post-closing to support operations and R&D.
- Forward-Looking Statements: The filing contains forward-looking statements regarding anticipated benefits, timing, and financial conditions, which are subject to various risks and may not materialize.
Investor Verification Checklist
- Verify the final amount of cash in the Petra Trust Account at closing, considering potential stockholder redemptions.
- Confirm the status and enrollment progress of Revelation's RVL-CLR01 clinical study.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed terms of the business combination and redemption rights.
- Assess the impact of the lack of a minimum funding requirement in the trust fund on Revelation's post-merger liquidity.
- Monitor regulatory updates regarding Revelation's product candidates and the potential for FDA or EMA approval.